PegBio Co

PegBio Co Net Tangible Assets

The Net Tangible Assets of PegBio Co (2565.HK) as of Nov 18, 2026 is 448.49 M CNY. In the previous year, Net Tangible Assets was 51.33 M CNY — a change of 773.79% (higher).

Net Tangible Assets

448.49 MCNY

YoY

773.79%

Last updated:

Net Tangible Assets of PegBio Co is 2025 448.49 M CNY. Net Tangible Assets of PegBio Co was 2024 51.33 M CNY. It decreases by 773.79% higher compared to the previous year.

The PegBio Co Net Tangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Tangible Assets
Date
Net Tangible Assets
Jan 1, 2022
299.97 M CNY
Jan 1, 2023
188.91 M CNY
Jan 1, 2024
51.33 M CNY
Jan 1, 2025
448.49 M CNY
The PegBio Co Net Tangible Assets history
YEARNet Tangible AssetsYoY
448.49 MCNY+773.79%
51.33 MCNY-72.83%
188.91 MCNY-37.02%
299.97 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PegBio Co Stock analysis

What does PegBio Co do? PegBio Co., Ltd. generates revenue primarily through the development and commercialization of innovative drugs targeting chronic and metabolic diseases. The company's flagship product, PB-119, is a near-commercialized long-acting GLP-1 receptor agonist designed for treating type 2 diabetes and obesity. Product candidates such as PB-718, PB-1902, PB-722, PB-2301, and PB-2309 are in development for indications including non-alcoholic steatohepatitis, opioid-induced constipation, and congenital hyperinsulinemia. The company focuses on pharmaceutical markets for chronic disease treatment, targeting patients and healthcare providers seeking advanced therapeutic solutions. PegBio's revenue streams are derived from the sale of PB-119 once it reaches commercialization, alongside potential future sales of its pipeline products. The firm targets healthcare systems and medical professionals in China, where it is headquartered, to address high-prevalence conditions like type 2 diabetes and obesity. Its product portfolio addresses unmet medical needs in metabolic disorders, positioning PegBio to capture market share in the growing biotechnology sector. The company's business model centers on developing proprietary drug candidates with strong clinical potential. PB-119, as a near-commercialized asset, is expected to drive initial revenue, while the broader pipeline of products like PB-718 and PB-2301 targets expanding therapeutic areas. PegBio aims to establish itself as a leader in chronic disease therapeutics through a focused approach on metabolic and endocrine conditions. PegBio Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PegBio Co stock

Net Tangible Assets of PegBio Co is 448.49 M CNY in 2025.

Net Tangible Assets of PegBio Co changed from 51.33 M CNY to 448.49 M CNY, representing a 773.79% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Tangible Assets PegBio Co since 2006 – with annual values, charts, and detailed analysis.

Net tangible assets equal total assets minus intangible assets, goodwill, and liabilities. They represent the physical asset backing of a company.

Net Tangible Assets's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Tangible Assets's PegBio Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — PegBio Co

All Key Metrics — PegBio Co